FO
NBRV

FT Options’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

FT Options’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$164K Buy
80
+20
+33% +$46.9K 0.25% 76
2017
Q2 		$170K Sell
60
-19
-24% -$49K 0.29% 61
2017
Q1 		$238K Sell
79
-253
-76% -$615K 0.31% 70
2016
Q4 		$494K Buy
332
+100
+43% +$133K 0.57% 42
2016
Q3 		$414K Buy
232
+34
+17% +$65.6K 0.33% 64
2016
Q2 		$372K Buy
198
+105
+113% +$212K 0.32% 63
2016
Q1 		$208K Buy
+93
New +$200K 0.22% 83

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

FT Options's NBRV Position: Q3 2017 in Review

FT Options increased its Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) stake by 33% in Q3 2017, buying an estimated $46.9K and bringing the position to 80 shares worth $164K. The position accounts for 0.25% of the portfolio, ranked #76.

FT Options first reported a position in NBRV in Q1 2016 and has held it in 7 quarters since. The position peaked at $494K in Q4 2016. 41 funds tracked by Wall St. Rank hold NBRV as of Q3 2017.

  • FT Options held 80 shares of Nabriva Therapeutics plc Ordinary Shares Ireland worth $164K as of Q3 2017.
  • FT Options bought 20 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2017, an estimated $46.9K.
  • Nabriva Therapeutics plc Ordinary Shares Ireland made up 0.25% of FT Options's portfolio in Q3 2017, its #76 holding.
  • FT Options first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2016 and has held it in 7 quarters since.
  • FT Options's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $494K in Q4 2016.
  • 41 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.